IonMed
Cold Plasma Bio-welding Technology for Wound Closure
Company Overview
Snapshot
Founded in November 2009 by Ronen Lam and Amnon Lam, IonMed operated with 1–10 employees. The company secured funding across two rounds from three investors. A significant milestone was achieved in October 2014 when IonMed received CE Mark clearance for its BioWeld1 cold plasma system.
Business overview
IonMed developed a plasma-based technology, BioWeld1, for advanced wound and surgical incision closure, and skin-graft fixation. This cold plasma device, complete with disposable tips and a biological film, facilitates hemostasis and closer approximation of incision or skin-graft edges, supporting the natural healing process. The company targeted the healthcare market, particularly operating rooms, doctors, and hospitals, operating within the Health Tech & Life Sciences sector, focusing on medical devices and medical treatment & therapeutics.
Strategic signal
In October 2014, IonMed received CE Mark clearance for its BioWeld1 cold plasma system. This regulatory approval was a critical validation of the technology's safety and efficacy, enabling its commercialization in European markets. For investors, this signaled a significant de-risking event and a clear path to market entry for a novel medical device in wound care.
Company Intelligence Q&A
- What is IonMed's core technology?
- IonMed's core technology is the BioWeld1 cold plasma system, designed for wound and surgical incision closure and skin-graft fixation. It uses cold plasma applied along Chitoplast strips to achieve hemostasis and improve the approximation of wound edges.
- When was IonMed founded and by whom?
- IonMed was founded in November 2009 by co-founders Ronen Lam and Amnon Lam.
- What was a key regulatory achievement for IonMed?
- In October 2014, IonMed received CE Mark clearance for its BioWeld1 cold plasma system, allowing its use for surgical incision closure in Europe. The system is also certified to the ISO13845 standard.
- Which investors participated in IonMed's funding rounds?
- In December 2009, IonMed received funding from The Trendlines Group and General Oriental Investments. In July 2011, Crossroad Venture Capital Fund invested in the company.
- What was the outcome of IonMed's first European clinical study?
- In May 2013, IonMed announced the successful completion of its first European clinical study for the closure of surgical wounds using its cold plasma technology.